Microbot Medical, manufacturer and distributer of the Liberty endovascular robotic system, today announced that the Japanese Patent Office has granted the company its first patent, which covers the core Liberty system technology—a compact robotic device for driving and manipulating movement of at least one elongate surgical tool.
In addition to today’s news, the company has also received patents in the USA, China and Israel over the past 90 days.
The company announced marketing clearance for the LIBERTY system by the US Food and Drug Administration (FDA) on 8 September 2025 and has accelerated its commercial launch plans as it targets an estimated 2.5 million peripheral endovascular procedures performed in the USA, annually.
A recent press release made by the company states that as it evaluates other future global markets that have historically accepted FDA cleared devices, the successful implementation of its global intellectual property strategy is expected to protect and allow it to monetise its innovative technology.
“Our initial focus is on the US market, however, certain markets such as Japan, represent attractive and strategically important markets for the Liberty system,” commented Harel Gadot, chairman, chief executive officer and president of Microbot Medical. “Building on our recent FDA clearance of Liberty, we are evaluating opportunities to expand into other global markets that have traditionally taken FDA clearance into consideration to potentially expedite local approval and adoption.”
